国际妇产科学杂志

国际妇产科学杂志 ›› 2009, Vol. 36 ›› Issue (5): 341-342.

• 述评 •    下一篇

新辅助化疗在晚期卵巢癌中的疗效评价

瞿全新; 糜若然   

  1. 300192 天津市第一中心医院妇产科(瞿全新); 天津医科大学总医院妇产科(糜若然)
  • 收稿日期:2008-12-17 修回日期:1900-01-01 出版日期:2009-10-15 发布日期:2009-10-15

Evaluation on Neoadjuvant Chemotherapy in Advanced Ovarian Carcinoma

QU Quan-xin; MI Ruo-ran   

  1. Department of Gynecology and Obstetrics in Tianjin First Central Hospital, Tianjin 300192, China(QU Quan-xin); Department of Gynecology and Obstetrics in Tianjin Medical University General Hospital, Tianjin 300052, China (MI Ruo-ran)
  • Received:2008-12-17 Revised:1900-01-01 Published:2009-10-15 Online:2009-10-15

PDF (PC)

4850

被引次数

19

摘要： 卵巢癌是目前复发率、病死率较高的妇科恶性肿瘤，特别是晚期卵巢癌，其中肿瘤细胞减灭术未能切除的大块残留病灶是导致患者术后化疗耐药、复发及预后不良的重要原因。近三十年的临床观察证实，新辅助化疗可缩小晚期卵巢癌原发灶及转移灶的体积，提高理想细胞减灭术的成功率，从而改善患者预后。近年临床观察发现，虽然新辅助化疗能提高部分晚期卵巢癌手术彻底性，但患者生存期并未得到有效延长。因此需要对新辅助化疗在晚期卵巢癌中的疗效及意义进行客观评价。

关键词: 卵巢癌, 新辅助化疗, 细胞减灭术

Abstract: Ovarian cancer, especially for advanced ovarian cancer, is a kind of common gynecologic malignant tumor with higher rate of relapse and death. It is the main reason that bulk unremovable tumor after cytoreductive surgery result in multidrug resistance, relapse and bad prognosis. It has been testified for nearly thirty years that neoadjuvant chemotherapy could reduce tumor volume, improve optimal cytoreduction rate and prognosis. However improved optimal cytoreduction rate failed to prolong the median lifetime. Therefore, we should evaluate objectively for the efficacy of neoadjuvant chemotherapy in advanced ovarian cancer based on the clinical meta-analysis.

Key words: Ovarian cancer, Neoadjuvant, Chemotherapy